Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
Bevacizumab and cetuximab both improve treatment efficacy when administered with chemotherapy for metastatic colorectal carcinoma (mCRC). Cetuximab has enhanced efficacy in Kras wild-type tumors. However, inferior outcomes have been demonstrated concerning the concurrent use of bevacizumab and cetux...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
D.A. Spandidos
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573099/ |